#Simcere

Thiard News@F4F

@newsen.bsky.social

1 month ago

Boehringer Ingelheim and Simcere Forge Partnership for Dual-Targeted Antibody Therapy in IBD Treatment Boehringer Ingelheim and Simcere join forces to develop a novel dual-targeted antibody therapy, aiming to transform inflammatory bowel disease treatment worldwide.

Boehringer Ingelheim and Simcere Forge Partnership for Dual-Targeted Antibody Therapy in IBD Treatment #China #Shanghai #Boehringer_Ingelheim #IBD_treatment #Simcere

Thiard News@F4F

@newsen.bsky.social

1 month ago

Boehringer Ingelheim and Simcere Partner for IBD Treatment Innovation Boehringer Ingelheim and Simcere have entered a partnership to develop a dual-target antibody aimed at addressing unmet needs in inflammatory bowel disease, potentially altering patient outcomes significantly.

Boehringer Ingelheim and Simcere Partner for IBD Treatment Innovation #China #Shanghai #Boehringer_Ingelheim #IBD_treatment #Simcere

pharmaphorum

@pharmaphorum.bsky.social

1 month ago

#BoehringerIngelheim has added another drug to its #immunology pipeline, #licensing an inflammatory bowel disease (#IBD) candidate from China's #Simcere in a deal that would be worth up to €1.05 billion ($1.25 billion).

buff.ly/IgGNk6v

Thiard News@F4F

@newsen.bsky.social

1 month ago

Boehringer Ingelheim and Simcere Collaborate on Novel Treatment for Inflammatory Bowel Disease Boehringer Ingelheim and Simcere announce a partnership to develop SIM0709, a dual-target antibody, to tackle inflammatory bowel disease (IBD) effectively.

Boehringer Ingelheim and Simcere Collaborate on Novel Treatment for Inflammatory Bowel Disease #China #Shanghai #Boehringer_Ingelheim #Simcere #SIM0709

Thiard News@F4F

@newsen.bsky.social

1 month ago

Boehringer Ingelheim Teams with Simcere to Innovate IBD Treatment Boehringer Ingelheim has partnered with Simcere to develop a bispecific antibody targeting inflammatory bowel disease, aiming to meet significant unmet medical needs.

Boehringer Ingelheim Teams with Simcere to Innovate IBD Treatment #China #Shanghai #Boehringer_Ingelheim #IBD_treatment #Simcere

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's Mutant IL-2 Fusion Protein SIM0278 Enters Phase II Clinical Trials Simcere Pharmaceutical Group announces the advancement of SIM0278, a mutant IL-2 fusion protein, into Phase II clinical trials targeting moderate to severe atopic dermatitis.

Simcere's Mutant IL-2 Fusion Protein SIM0278 Enters Phase II Clinical Trials #China #Hangzhou #Atopic_Dermatitis #Simcere #SIM0278

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials Simcere Pharmaceutical Group has announced that its mutant IL-2 fusion protein, SIM0278, has entered Phase II clinical trials for the treatment of moderate to severe atopic dermatitis.

Simcere's Breakthrough IL-2 Mutant Protein SIM0278 Advances to Phase II Trials #China #Hangzhou #Atopic_Dermatitis #Simcere #SIM0278

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere Launches Phase II Clinical Trials for SIM0278, a Mutant IL-2 Fusion Protein Simcere Pharmaceutical has begun Phase II trials of SIM0278, a mutant IL-2 protein aimed at treating moderate to severe atopic dermatitis. This significant step seeks to enhance patient care globally.

Simcere Launches Phase II Clinical Trials for SIM0278, a Mutant IL-2 Fusion Protein #China #Nanjing #Simcere #SIM0278 #IL-2

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's Innovative IL-2 Mutant Fusion Protein Enters Phase II Trials to Combat Atopic Dermatitis Simcere Pharmaceutical’s IL-2 mu-Fc, SIM0278, has entered Phase II clinical trials in China for treating moderate-to-severe atopic dermatitis, offering new hope to patients.

Simcere's Innovative IL-2 Mutant Fusion Protein Enters Phase II Trials to Combat Atopic Dermatitis #China #Hangzhou #Atopic_Dermatitis #Simcere #SIM0278

Thiard News@F4F

@newsen.bsky.social

4 months ago

Simcere's New IL-2 Mutant Fusion Protein Enters Phase II Trials to Fight Atopic Dermatitis Simcere Pharmaceutical’s novel IL-2 mutant protein, SIM0278, has entered Phase II clinical trials, targeting moderate-to-severe atopic dermatitis in patients.

Simcere's New IL-2 Mutant Fusion Protein Enters Phase II Trials to Fight Atopic Dermatitis #China #Hangzhou #Simcere #SIM0278 #IL-2_Mutant

Thiard News@F4F

@newsen.bsky.social

8 months ago

First Patient Dosed with SIM0500 in US Trial for Multiple Myeloma Combat Simcere Zaiming has initiated a Phase 1 trial of SIM0500 for treating relapsed/refractory multiple myeloma in the US, marking a crucial step in oncology.

First Patient Dosed with SIM0500 in US Trial for Multiple Myeloma Combat #USA #New_York #Simcere #Zaiming #SIM0500

Thiard News@F4F

@newsen.bsky.social

1 year ago

Fermion and Simcere Team Up to Develop China's First SSTR4 Agonist for Pain Relief Guangzhou Fermion and Simcere Pharmaceutical are collaborating to create China's first selective SSTR4 agonist, targeting effective pain management without addiction risks.

Fermion and Simcere Team Up to Develop China's First SSTR4 Agonist for Pain Relief #China #Guangzhou #Simcere #Fermion #FZ002-037

Thiard News@F4F

@newsen.bsky.social

1 year ago

Fermion and Simcere Form Exclusive Partnership for SSTR4 Pain Treatment Development Guangzhou Fermion Technology and Simcere Pharmaceutical have announced a collaboration to develop a groundbreaking SSTR4-targeted pain relief treatment in China, offering hope for chronic pain sufferers.

Fermion and Simcere Form Exclusive Partnership for SSTR4 Pain Treatment Development #China #Guangzhou #Simcere #Fermion #SSTR4

Thiard News@F4F

@newsen.bsky.social

1 year ago

Fermion and Simcere Forge Partnership for Pain Relief Drug Development in China Fermion and Simcere have partnered to develop China's first SSTR4 agonist, targeting pain relief. The innovative drug promises minimal side effects.

Fermion and Simcere Forge Partnership for Pain Relief Drug Development in China #China #Guangzhou #Simcere #Fermion #SSTR4

Thiard News@F4F

@newsen.bsky.social

1 year ago

New Partnership to Develop China's First SSTR4 Agonist for Pain Management Guangzhou Fermion and Simcere Pharmaceutical join forces to develop FZ002-037, the first SSTR4 agonist in China, aiming for effective pain relief.

New Partnership to Develop China's First SSTR4 Agonist for Pain Management #China #Guangzhou #Simcere #Fermion #SSTR4_Agonist

Thiard News@F4F

@newsen.bsky.social

1 year ago

Fermion and Simcere Unite to Combat Pain with Revolutionary SSTR4 Agonist Fermion and Simcere have partnered to develop FZ002-037, China’s first SSTR4 agonist aimed at revolutionizing pain management without addiction risks.

Fermion and Simcere Unite to Combat Pain with Revolutionary SSTR4 Agonist #China #Guangzhou #Simcere #Fermion #SSTR4_Agonist

Thiard News@F4F

@newsen.bsky.social

1 year ago

Simcere's Sanbexin® Sublingual Tablets Approved for Acute Ischemic Stroke Treatment Simcere Pharmaceutical's Sanbexin® sublingual tablets have received Chinese approval for treating acute ischemic stroke, promising significant improvements in recovery.

Simcere's Sanbexin® Sublingual Tablets Approved for Acute Ischemic Stroke Treatment #China #Nanjing #Simcere #Sanbexin #Stroke_Treatment